Article Details

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the ...

Retrieved on: 2021-07-21 04:52:30

Tags for this article:

Click the tags to see associated articles and topics

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the .... View article details on hiswai:

Excerpt

“Higher-risk MDS is associated with poor prognosis, reduced quality of life, and limited treatment options,” said Levi Garraway, M.D., Ph.D., Roche's ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up